• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    10/5/23 1:31:18 PM ET
    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email

    Gainers

    • Orchard Therapeutics (NASDAQ:ORTX) shares increased by 96.5% to $15.99 during Thursday's regular session. As of 13:31 EST, Orchard Therapeutics's stock is trading at a volume of 7.9 million, which is 17105.9% of its average full-day volume over the last 100 days. The company's market cap stands at $363.4 million.
    • Histogen (NASDAQ:HSTO) shares moved upwards by 47.17% to $0.75. Trading volume for Histogen's stock is 414.2K as of 13:31 EST. This is 163.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.1 million.
    • Clene (NASDAQ:CLNN) stock moved upwards by 21.0% to $0.6. Trading volume for this security as of 13:31 EST is 2.1 million, which is 481.4% of its average full-day volume over the last 100 days. The company's market cap stands at $76.7 million.
    • Orgenesis (NASDAQ:ORGS) stock increased by 19.98% to $0.78. Trading volume for this security as of 13:31 EST is 145.2K, which is 158.0% of its average full-day volume over the last 100 days. The company's market cap stands at $23.7 million.
    • Omega Therapeutics (NASDAQ:OMGA) shares increased by 19.4% to $2.06. The current volume of 542.6K shares is 433.9% of Omega Therapeutics's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $113.5 million.
    • Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 15.85% to $0.14. The current volume of 6.3 million shares is 880.7% of Matinas BioPharma Hldgs's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $30.9 million.

    Losers

    • MaxCyte (NASDAQ:MXCT) shares declined by 22.6% to $2.53 during Thursday's regular session. MaxCyte's stock is trading at a volume of 3.2 million shares as of 13:31 EST. This is 749.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $261.8 million.
    • Longeveron (NASDAQ:LGVN) stock decreased by 17.93% to $2.06. The current volume of 9.2 million shares is 7502.9% of Longeveron's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $43.6 million.
    • Viracta Therapeutics (NASDAQ:VIRX) stock declined by 17.39% to $0.76. As of 13:31 EST, Viracta Therapeutics's stock is trading at a volume of 343.5K, which is 439.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.3 million.
    • Nanobiotix (NASDAQ:NBTX) stock decreased by 17.14% to $7.45. The company's market cap stands at $259.6 million.
    • SenesTech (NASDAQ:SNES) stock decreased by 16.29% to $0.37. SenesTech's stock is trading at a volume of 183.9K shares as of 13:31 EST. This is 266.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.1 million.
    • Renalytix (NASDAQ:RNLX) stock declined by 16.11% to $1.25. Renalytix's stock is trading at a volume of 98.2K shares as of 13:31 EST. This is 69.2% of its average full-day volume over the last 100 days. The company's market cap stands at $59.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN
    $HSTO
    $LGVN
    $MTNB

    CompanyDatePrice TargetRatingAnalyst
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    MaxCyte Inc.
    $MXCT
    8/11/2025Buy → Neutral
    BTIG Research
    MaxCyte Inc.
    $MXCT
    8/7/2025Outperform → Mkt Perform
    William Blair
    MaxCyte Inc.
    $MXCT
    7/22/2025$6.00Overweight
    Stephens
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    Omega Therapeutics Inc.
    $OMGA
    11/15/2024Outperform → Mkt Perform
    Raymond James
    Nanobiotix S.A.
    $NBTX
    8/28/2024$12.00Buy
    Guggenheim
    Viracta Therapeutics Inc.
    $VIRX
    8/16/2024$5.00 → $3.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

    In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026Oversubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDACompletion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027 SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Cl

    3/12/26 8:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    SEC Filings

    View All

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    3/12/26 4:35:12 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SenesTech, Inc. (0001680378) (Filer)

    3/12/26 4:06:15 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Longeveron Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    3/12/26 4:05:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $15,480 worth of shares (8,569 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/6/26 5:40:20 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MaxCyte downgraded by BTIG Research

    BTIG Research downgraded MaxCyte from Buy to Neutral

    8/11/25 9:48:40 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte downgraded by William Blair

    William Blair downgraded MaxCyte from Outperform to Mkt Perform

    8/7/25 7:35:46 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:57 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wilcox Reed N

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:22 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mosca Alison

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:04:47 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Announces CEO Transition Plan

    Board To Initiate Search For New Leadership As Current CEO Plans Retirement Dr. Jamie Bechtel Named Interim Executive Chair To Further Support Transition PHOENIX, Jan. 28, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a pioneer in fertility control solutions for managing rodent populations, today announced that Joel Fruendt, President and Chief Executive Officer, has informed the Board of Directors of his intent to retire. The Board will commence a formal search for a successor. Mr. Fruendt will continue to serve as President and CEO until the search is completed or until June 30, 2026, whichever occurs first.

    1/28/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Financials

    Live finance-specific insights

    View All

    SenesTech Announces 2025 Financial Results Driven by Strong Growth in E-Commerce

    SURPRISE, Ariz., March 12, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, today announced financial results for the fourth quarter and the full year ended December 31, 2025. 2025 HighlightsRevenue increased by 20% to $2.2 million in 2025 as compared to 2024, driven by strong growth in the Company's overall e-commerce channels despite the impact associated with the Company's transition to directly managing Amazon sales of Evolve® Rat and Evolve Mouse. Excluding this transition-related impact, we estimate re

    3/12/26 4:05:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026

    MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

    3/12/26 9:00:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $CLNN
    $HSTO
    $LGVN
    $MTNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:51:18 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

    SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

    12/4/24 6:50:26 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials